Roth/MKM Reiterates Buy Rating on BioRestorative Therapies Inc. (BRTX)

Roth/MKM analyst Jonathan Aschoff reiterated a Buy rating and $15.00 price target on BioRestorative Therapies Inc. (NASDAQ: BRTX)

The analyst comments "BRTX ended 1Q24 with $16.4M in cash. In February, BRTX released encouraging, preliminary, blinded Phase 2 results with BRTX-100 in the first four cLDD patients treated. Although still blinded, there appears to be an encouragingly tight grouping of efficacy results among three patients showing better outcomes on four endpoints than seen with the fourth patient, and the initial four patients were randomized 3:1. BRTX's commercial-stage biocosmeceutical business is operational, with annual minimum purchases that we estimate in the low millions over five years with Cartessa."

For an analyst ratings summary and ratings history on BioRestorative Therapies Inc. click here. For more ratings news on BioRestorative Therapies Inc. click here.

Shares of BioRestorative Therapies Inc. closed at $1.17 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Full Circle Lithium closes $5.14M private placement
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'